Cellectar raises $19.4M via warrant exercise; new warrants could add $73.3M

Cellectar Biosciences, Inc.

Gross proceeds of ~$19.4M from exercise of Tranche B warrants at reduced price of $2.52/share.
New Tranche A, B, C warrants could generate up to $73.3M additional gross proceeds if exercised.
Tranche A warrants ($2.52 exercise) trigger on FDA assigning PDUFA date for iopofosine I 131.
Tranche B ($4.00) triggers on FDA approval; Tranche C ($5.50) on quarterly revenue >$10M from iopofosine.
Company expects to file NDA for iopofosine I 131 in Q4 2024, seeking priority review.

item 1.01 item 3.02 item 3.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.